T-cell large granular lymphocytic leukemia (T-LGLL) is a rare lymphoproliferative disorder and can cooccur in the context of pure red cell aplasia (PRCA). The aim of the current study was to analyze the signal transducer and activator of transcription 3 (STAT3) mutation status and its clinical significance in T-LGLL. We found STAT3 mutations in 21.4% of patients with T-LGLL. High β2-MG (β2-microglobulin) levels (P = 0.005), neutropenia (P = 0.018) and PRCA (P = 0.001) all displayed a significant association with STAT3 mutations. In univariate analysis, treatment-free survival (TFS) was affected by STAT3 mutation status (P = 0.008) and β2-MG (P = 0.006). Our results demonstrate the remarkable correlation of STAT3 mutation with PRCA, neutropenia and β2-MG.

1. Colorectal Cancer (CRC) is the third most common cancer worldwide and the second leading cause of cancer-related deaths1. The occurrence and development of CRC are influenced by a combination of...

Colorectal cancer (CRC) ranks as the third most prevalent malignancy globally based on recent epidemiological studies. In China, the rising incidence and mortality rates of CRC have underscored the importance of elucidating its pathogenic mechanisms, which remain major focus in current biomedical research. Ferroptosis, a regulated cell death process driven by iron-dependent lipid peroxidation, is closely associated with disruptions in iron homeostasis, lipid metabolism, and amino acid metabolism. This unique iron-catalysed death process plays a crucial role in both tumor initiation and malignant progression by disturbing cellular redox imbalance. The cystine/glutamate antiporter SLC7A11 (also known as xCT) has been identified as a central regulator of ferroptosis susceptibility. The tumor suppressor p53 and its associated microRNAs modulate ferroptotic responses through regulation of SLC7A11 expression, forming a critical axis in oncogenic transformation and metastasis. However, the precise role of SLC7A11 in CRC—particularly its context-dependent dual functions as both a tumor promoter and a therapeutic vulnerability—remains a critical unanswered question. This review aims to systematically summarize current advances in understanding the multiple roles of SLC7A11 in CRC-related ferroptosis pathways and to evaluate emerging therapeutic strategies targeting this axis. Importantly, we also underscore the existing knowledge gaps and outline future research directions essential for leveraging this unique molecular pathway to improve patient outcomes.

This study assessed the efficacy and safety of HyperArc (HA) stereotactic radiotherapy (SRT) in 48 patients with lung cancer brain metastases (LCBM) while identifying prognostic factors and high-risk predictors for symptomatic cerebral radiation necrosis (sCRN). We enrolled 48 patients diagnosed with LCBM at the People’s Hospital Affiliated to Jiangsu University between February 2021 and February 2025, assigning 44 to the SRT group and 4 to the WBRT-boost group. Clinical data were collected, and all patients underwent HA stereotactic radiotherapy. The WBRT-boost group additionally received a local HA boost. Prescription doses of 24–30 Gy were administered in 3–5 fractions at 5 fractions weekly, tailored to lesion characteristics. We evaluated both the efficacy and safety of HA treatment for LCBM. The 1-year overall survival (OS), intracranial distant progression-free survival (iDPFS), and intracranial local progression-free survival (iLPFS) rates for the entire cohort were 76.1, 64.5, and 69.4%, respectively. For out-of-field distant metastases, the cumulative intracranial objective response rate (icORR) and intracranial disease control rate (icDCR) reached 52.1 and 64.6%, compared with 81.2 and 97.9% for in-field metastases. The WBRT-boost group exhibited a median OS of 6.6 months, while the SRT group achieved superior 1-year outcomes (OS:79.1%; iDPFS:67.0%; iLPFS:71.8%). Compared with WBRT-boost, SRT showed significantly better local control (iLPFS, P = 0.044) and overall survival (OS, P = 0.036), though distant control (iDPFS, P = 0.086) did not differ significantly. Multivariate analysis identified V12 > 10 cc (HR 12.52, P = 0.011) and female sex (HR 11.66, P = 0.026) as independent prognostic factors. All 12 symptomatic radiation necrosis cases (27.3%) occurred in the SRT group. Logistic regression demonstrated that higher BED3 (HR 57.0, P = 0.009) independently increased sCRN risk, whereas targeted therapy (HR 0.08, P = 0.024) significantly reduced it. HyperArc-based fractionated stereotactic radiotherapy proves safe and feasible for managing brain metastases from lung cancer, achieving effective intracranial tumor control. Compared with WBRT + boost, SRT yields superior therapeutic outcomes despite requiring careful monitoring for symptomatic radiation necrosis. Further investigations should examine combined approaches incorporating targeted agents and optimized dose distribution.

Objective: To predict the risk factors of radiation pneumonitis (RP) in patients with esophageal squamous cell carcinoma (ESCC) who received radiotherapy.Methods: From January 2015 to October 2021, 477 ESCC patients were enrolled and were assessed retrospectively. All these patients received radiotherapy for primary lesions or mediastinal metastatic lymph nodes. Clinical efficacy and adverse events (AEs) were observed. Univariate analysis identified clinical and dosimetric factors associated with the development of RP, and multivariate logistic regression analysis identified independent potential risk factors associated with the development of RP. Nomograms were constructed to predict RP based on the results of multivariate logistic regression analysis.Results: Among the 477 ESCC patients, the incidence of RP was 22.2%, and the incidence of grade 4 or higher RP was 1.5%. Univariate analysis indicated that chronic obstructive pulmonary disease (COPD), pulmonary infection, leucopenia, PTV volume, V5, V20, V30 and MLD affected the occurrence of RP. The multivariate logistic regression analysis indicated that COPD (OR:1.821, 95%CI:1.111-2.985; P=0.017), pulmonary infection (OR:2.528, 95%CI:1.530-4.177; P<0.001), higher V20 (OR: 1.129, 95% CI:1.006-1.266; P=0.029) were significant independent predictors of RP in ESCC patients. COPD, pulmonary infection, V20 have been integrated for the RP nomogram. The rate of RP was significantly reduced in the V20<21.45% group. Further analysis indicated that the old age, diabetes, higher V20, and higher MLD were risk factors for grade 4 or higher RP. The area under the curve (AUC) value for V20 was 0.73 (95% CI, 0.567-0.893, P < 0.05).Conclusion: We have determined the risk factors of RP and grade 4 or higher RP in ESCC patients after radiotherapy. MLD, V20, COPD were independent factors for RP. It was necessary to take measures to reduce or avoid the occurrence of RP for patients with these risk factors at the early stage.

Previous studies suggested that miR-146a rs2910164 (C/G) locus was predicted to influence the risk of cancer. However, the relationship of miR-146a rs2910164 locus with colorectal cancer (CRC) susceptibility was controversial. We recruited 1,003 CRC patients and 1,303 controls and performed a case-control study to clarify the correlation of miR-146a rs2910164 locus with CRC risk. Subsequently, a comprehensive meta-analysis was conducted to verify our findings. In the case-control study, we suggested that miR-146a rs2910164 variants did not alter CRC risk (CG vs. CC: adjusted P=0.465; GG vs. CC: adjusted P=0.436, CG/GG vs. CC: adjusted P=0.387 and GG vs. CC/CG: adjusted P = 0.589), even in subgroup analysis. Next, we conducted a pooled-analysis to identify the correlation of miR-146a rs2910164 locus with CRC risk. In this pooled-analysis, 7,947 CRC cases and 12,168 controls were included. We found that miR-146a rs2910164 polymorphism did not influence the risk of CRC (G vs. C: P=0.537; GG vs. CC: P=0.517, CG/GG vs. CC: P=0.520 and GG vs. CC/CG: P=0.167). Our findings suggest that miR-146a rs2910164 C/G polymorphism is not correlated with the susceptibility of CRC. In the future, more case-control studies are needed to confirm our results.